Takuji Shoda
Affiliations: | 2012 | Yale University, New Haven, CT |
Google:
"Takuji Shoda"Mean distance: 8.42 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yamano K, Kikuchi R, Kojima W, et al. (2020) Critical role of mitochondrial ubiquitination and the OPTN-ATG9A axis in mitophagy. The Journal of Cell Biology. 219 |
| Shoda T, Ohoka N, Tsuji G, et al. (2020) Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety. Pharmaceuticals (Basel, Switzerland). 13 |
| Ohoka N, Tsuji G, Shoda T, et al. (2019) Development of small molecule chimeras that recruit AhR E3 ligase to target proteins. Acs Chemical Biology |
| Ohoka N, Tsuji G, Shoda T, et al. (2019) Abstract C125: Development of small molecule chimeras that recruit aryl-hydrocarbon receptor (AhR) E3 ligase to induce degradation of target proteins Molecular Cancer Therapeutics. 18 |
| Tsuji G, Hattori T, Kato M, et al. (2018) Design and synthesis of cell-permeable fluorescent nitrilotriacetic acid derivatives. Bioorganic & Medicinal Chemistry |
| Misawa T, Fujisato T, Kanda Y, et al. (2017) Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton. Medchemcomm. 8: 239-246 |
| Okitsu K, Misawa T, Shoda T, et al. (2017) Development of an ON/OFF switchable fluorescent probe targeting His tag fused proteins in living cells. Bioorganic & Medicinal Chemistry Letters |
| Okitsu K, Hattori T, Misawa T, et al. (2017) Development of a small hybrid molecule that mediates degradation of His-tag fused proteins. Journal of Medicinal Chemistry |
| Okuhira K, Shoda T, Omura R, et al. (2016) Targeted degradation of proteins localized in subcellular compartments by hybrid small molecules. Molecular Pharmacology |
| Demizu Y, Shibata N, Hattori T, et al. (2016) Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorganic & Medicinal Chemistry Letters |